NeOnc CEO buys more stock after positive NEO100 Phase 2a data

NeOnc Technologies Holdings, Inc. disclosed in an 8-K filed September 17, 2026 that Executive Chairman, President and CEO Amir F. Heshmatpour purchased an additional 35,000 shares of NeOnc common stock in the open market on September 15, 2026, for approximately $115,400, at a weighted average price of approximately $3.30 per share, as will be reported in a Form 4 filed with the SEC.¹

The company said the purchase follows the company's $15 million registered direct offering announced on September 9, 2026, and extends a series of open-market purchases by NeOnc's senior leadership since the company reported positive topline Phase 2a results for intranasal NEO100 on August 12, 2026.¹ Since that announcement, Heshmatpour has purchased 111,000 shares for a total of approximately $418,700, at an average cost of approximately $3.77 per share.¹ Chief Medical and Scientific Officer Thomas C. Chen, MD, PhD, has purchased 49,016 shares for approximately $210,000.¹ Combined, the two executives have purchased 160,016 shares for approximately $629,000 in the open market, as reflected in Form 4 filings with the SEC, including the Form 4 to be filed for the September 15 purchases.¹

On the underlying trial, the company said the NEO100-01 Phase 2a study met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047), and median overall survival of 26.09 months.¹ The company noted its second clinical program, NEO212, has completed Phase 1 dose escalation and established a recommended Phase 2 dose.¹

The filing cautioned that the Phase 2a study was a single-arm, open-label study of 24 patients that did not reach its planned enrollment of 28 patients and was not powered as a confirmatory trial, and that the FDA may not agree with the company's proposed registrational path, endpoints, or analytical methods.¹ All purchases were made in the open market using personal funds.¹